Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Perspectives on Model‐Informed Precision Dosing in the Digital Health Era: Challenges, Opportunities, and Recommendations
Franziska Kluwe, Robin Michelet, Anna Mueller‐Schoell, et al.
Clinical Pharmacology & Therapeutics (2020) Vol. 109, Iss. 1, pp. 29-36
Open Access | Times Cited: 50

Showing 1-25 of 50 citing articles:

Artificial Intelligence and Machine Learning Approaches to Facilitate Therapeutic Drug Management and Model-Informed Precision Dosing
Ethan A. Poweleit, Alexander A. Vinks, Tomoyuki Mizuno
Therapeutic Drug Monitoring (2023) Vol. 45, Iss. 2, pp. 143-150
Open Access | Times Cited: 48
Implementation of Model-Informed Precision Dosing for Tamoxifen Therapy in Patients with Breast Cancer: A Prospective Intervention Study
Ruben Y M van Nijnatten, Sanne M. Buijs, Bram C. Agema, et al.
The Breast (2025) Vol. 79, pp. 103880-103880
Open Access | Times Cited: 1
Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing
Zachary L. Taylor, Ethan A. Poweleit, Kelli Paice, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 12, pp. 1827-1845
Open Access | Times Cited: 18
Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update
M. Briki, Amarande Murisier, Monia Guidi, et al.
Journal of Chromatography B (2024) Vol. 1236, pp. 124039-124039
Open Access | Times Cited: 7
From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology
Bram C. Agema, Birgit C. P. Koch, Ron H.J. Mathijssen, et al.
Drugs (2025)
Open Access
Personalized Dosing of Medicines for Children: A Primer on Pediatric Pharmacometrics for Clinicians
Kevin Meesters, Violeta Balbas‐Martinez, Karel Allegaert, et al.
Pediatric Drugs (2024) Vol. 26, Iss. 4, pp. 365-379
Closed Access | Times Cited: 3
Perceived barriers and facilitators for model-informed dosing in pregnancy: a qualitative study across healthcare practitioners and pregnant women
Charlotte Koldeweij, Mirèse Kleuskens, Carlijn H. C. Litjens, et al.
BMC Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr
Félicien Le Louedec, Florent Puisset, Fabienne Thomas, et al.
CPT Pharmacometrics & Systems Pharmacology (2021) Vol. 10, Iss. 10, pp. 1208-1220
Open Access | Times Cited: 21
C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework
Yomna Nassar, Francis Williams Ojara, Alejandro Pérez‐Pitarch, et al.
Cancers (2023) Vol. 15, Iss. 22, pp. 5429-5429
Open Access | Times Cited: 8
Willingness-to-use and preferences for model-informed antenatal doses: a cross-sectional study among European healthcare practitioners and pregnant women
Charlotte Koldeweij, Anna Caroline Dibbets, Michael Ceulemans, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Model-informed precision dosing to optimise immunosuppressive therapy in renal transplantation
Tom C. Zwart, Henk‐Jan Guchelaar, Paul J. M. van der Boog, et al.
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2527-2546
Open Access | Times Cited: 17
A continued learning approach for model‐informed precision dosing: Updating models in clinical practice
Corinna Maier, Jana de Wiljes, Niklas Hartung, et al.
CPT Pharmacometrics & Systems Pharmacology (2021) Vol. 11, Iss. 2, pp. 185-198
Open Access | Times Cited: 17
Machine learning advances the integration of covariates in population pharmacokinetic models: Valproic acid as an example
Xiuqing Zhu, Ming Zhang, Yuguan Wen, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 12
Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges
Hannah R. Wardill, Luke T. Wooley, Olivia M. Bellas, et al.
British Journal of Cancer (2023) Vol. 130, Iss. 1, pp. 19-30
Open Access | Times Cited: 6
Effect of Obesity on the Pharmacokinetics and Pharmacodynamics of Anticancer Agents
William C. Zamboni, Rosane Charlab, Gilbert J. Burckart, et al.
The Journal of Clinical Pharmacology (2023) Vol. 63, Iss. S2
Closed Access | Times Cited: 6
Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
Josefine Schulz, Antonia Thomas, Ayatallah Saleh, et al.
Pharmaceutics (2022) Vol. 14, Iss. 3, pp. 477-477
Open Access | Times Cited: 10
Applying machine learning to the pharmacokinetic modeling of cyclosporine in adult renal transplant recipients: a multi-method comparison
Junjun Mao, Yuhao Chen, Luyang Xu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
A prognostic baseline blood biomarker and tumor growth kinetics integrated model in paclitaxel/platinum treated advanced non‐small cell lung cancer patients
Francis Williams Ojara, Andrea Henrich, Nicolas Frances, et al.
CPT Pharmacometrics & Systems Pharmacology (2023) Vol. 12, Iss. 11, pp. 1714-1725
Open Access | Times Cited: 5
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol
Anna M. Mc Laughlin, Eduard Schmulenson, Olga Teplytska, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6281-6281
Open Access | Times Cited: 12
Precision Dosing: The Clinical Pharmacology of Goldilocks
Richard Peck, Mohamed H. Shahin, Alexander A. Vinks
Clinical Pharmacology & Therapeutics (2020) Vol. 109, Iss. 1, pp. 11-14
Open Access | Times Cited: 12
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature
Alia Fahmy, Ashley M. Hopkins, Michael J. Sorich, et al.
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 7, pp. 803-821
Closed Access | Times Cited: 11
Insights in the maturational processes influencing hydrocortisone pharmacokinetics in congenital adrenal hyperplasia patients using a middle-out approach
Robin Michelet, Davide Bindellini, Johanna Melin, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 4
A Physiologically Based Pharmacokinetic Model to Predict Determinants of Variability in Epirubicin Exposure and Tissue Distribution
Radwan Ansaar, Robyn Meech, Andrew Rowland
Pharmaceutics (2023) Vol. 15, Iss. 4, pp. 1222-1222
Open Access | Times Cited: 4
Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data
Franziska Kluwe, Robin Michelet, Wilhelm Huisinga, et al.
Clinical Pharmacokinetics (2023) Vol. 62, Iss. 10, pp. 1461-1477
Open Access | Times Cited: 4
Modeling the protein binding non-linearity in population pharmacokinetic model of valproic acid in children with epilepsy: a systematic evaluation study
Lina Zhang, Maochang Liu, Weiwei Qin, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top